Separin (SEPSECS) Protein

📖 Wiki Page

protein1848 wordssynced 2026-04-02

Separin (SEPSECS) Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Separin (SEPSECS) Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SEPSOCS</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Separin (SEPSECS)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=SEPSOCS" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>

Separin (encoded by the SEPSECS gene) is a 463-amino acid enzyme that catalyzes the final step in selenocysteine (Sec) biosynthesis, the 21st amino acid in the genetic code[@sep1]. Separin, also known as selenocysteine synthase or selenocysteine synthase (SecS), is essential for the synthesis of all selenoproteins in mammals, making it a critical enzyme for cellular function and survival[@sep2].

Selenium is incorporated into proteins as selenocysteine through a specialized translational process that requires a unique selenocysteine insertion sequence (SECIS) element in the mRNA, specific elongation factors, and Separin as the catalytic enzyme[@sep3]. This process is conserved from archaea to humans and represents one of the most complex translation mechanisms in biology.

...

Separin (SEPSECS) Protein

Overview

The SEPSECS gene is located on chromosome 4p16.3 and encodes a protein with a molecular weight of approximately 55 kDa. The enzyme is widely expressed in human tissues, with highest levels in the brain, liver, and kidneys, reflecting the high demand for selenoprotein synthesis in these organs[@sep4].

Structure

Domain Architecture

Separin contains three distinct functional domains:

N-terminal Domain (1-150 aa): This domain recognizes and binds to the acceptor stem of seryl-tRNA^Sec, the unique tRNA that carries selenocysteine during translation. The binding involves specific base-pairing interactions between the tRNA acceptor stem and conserved residues in the N-terminal domain[@sep5].

Central Catalytic Domain (151-350 aa): The central region contains the ATP-binding pocket and the active site cysteine residue. ATP hydrolysis provides the energy for the conversion of seryl-tRNA^Sec to selenocysteinyl-tRNA^Sec. This domain shows structural similarity to the MoeB protein in bacteria, reflecting the evolutionary relationship between selenocysteine synthesis and sulfur metabolism[@sep5].

C-terminal Domain (351-463 aa): The C-terminal domain is responsible for binding selenophosphate, the selenium donor substrate produced by selenophosphate synthetase (SELENOO). This domain contains a binding pocket that specifically recognizes the selenophosphate molecule[@sep1].

Catalytic Mechanism

Separin catalyzes the following reaction:
Seryl-tRNA^Sec + selenophosphate → selenocysteinyl-tRNA^Sec + phosphate

The catalytic mechanism involves:

ATP binding to the active site, forming an acyl-adenylate intermediate with seryl-tRNA^Sec

Phosphate release and formation of an enzyme-bound selenolate intermediate

Selenophosphate attack on the activated seryl moiety

Product release of selenocysteinyl-tRNA^Sec and phosphate[@sep6]

The enzyme requires Mg²⁺ as a cofactor and exhibits strict specificity for seryl-tRNA^Sec as the amino acid donor, rejecting all other tRNA-bound amino acids.

Normal Function

Selenocysteine Biosynthesis Pathway

Separin occupies a central position in selenoprotein synthesis, representing the gateway through which all selenocysteine-containing proteins are produced. The complete pathway involves multiple enzymes:

Step 1 - Selenophosphate Synthesis: Selenophosphate synthetase (SELENOO) converts selenide and ATP to selenophosphate, the reactive selenium donor[@sep4].

Step 2 - Serine Activation: Seryl-tRNA^Sec is generated by the action of arginyl-tRNA synthetase and the specialized Separin (but actually by O-phosphoseryl-tRNA^Sec kinase - PSTK), which first phosphorylates the serine on tRNA^Sec[@sep1].

Step 3 - Separin Catalysis: Separin catalyzes the substitution of the phosphate group with selenophosphate, producing selenocysteinyl-tRNA^Sec, the activated form ready for translational insertion[@sep2].

Step 4 - Translation: The ribosome, guided by the SECIS element in the mRNA, recognizes selenocysteinyl-tRNA^Sec and incorporates selenocysteine at in-frame UGA codons[@sep3].

Importance of Selenoproteins

Separin-mediated selenoprotein synthesis is essential for numerous critical cellular functions:

Antioxidant Defense: Glutathione peroxidases (GPX1, GPX2, GPX3, GPX4, GPX5, GPX6) use selenocysteine at their active sites to catalyze the reduction of hydrogen peroxide and organic hydroperoxides, protecting cells from oxidative damage[@sep7].

Redox Homeostasis: Thioredoxin reductases (TR1, TR11, TR2) contain selenocysteine and maintain the cellular redox balance by reducing thioredoxin and other substrates[@sep4].

Selenium Transport: Selenoprotein P (SELENOP) serves as the primary selenium transport protein in plasma and is essential for delivery of selenium to the brain and other tissues[@sep8].

ER Stress Response: Selenoprotein K (SELK) and selenoprotein S (SELENOS) are involved in protein folding quality control and ER-associated degradation (ERAD)[@sep9].

Thyroid Hormone Metabolism: Iodothyronine deiodinases (DIO1, DIO2, DIO3) convert thyroid hormones and are essential for systemic metabolism regulation[@sep2].

Role in Neurodegeneration

ALS and Separin

Mutations in SEPSECS have been implicated in early-onset progressive cerebello-cerebral atrophy (PCCA) and juvenile amyotrophic lateral sclerosis (ALS), demonstrating the critical importance of selenoprotein synthesis for neuronal survival[@sep8].

Mechanisms of Neurodegeneration:

Impaired Selenoprotein Synthesis: Loss-of-function mutations in SEPSECS lead to reduced synthesis of all selenoproteins, creating a multi-system deficit that particularly affects neurons with high metabolic demands[@sep8].

Oxidative Stress: Deficiency in antioxidant selenoproteins (particularly GPX4) leads to accumulation of reactive oxygen species, lipid peroxidation, and ferroptosis - a form of programmed cell death increasingly implicated in neurodegeneration[@sep7].

ER Stress: Impaired synthesis of ER-resident selenoproteins (SELK, SELENOS) compromises the unfolded protein response and ERAD pathways, making neurons vulnerable to protein aggregation stress[@sep9].

Mitochondrial Dysfunction: Selenoproteins are essential for mitochondrial integrity and function. Loss of Separin activity leads to mitochondrial fragmentation, loss of membrane potential, and impaired respiration[@sep14].

Synaptic Dysfunction: Selenoproteins play critical roles in synaptic vesicle function, neurotransmitter release, and dendritic spine morphology. Separin deficiency impairs these processes, leading to synaptic loss[@sep7].

Parkinson's Disease

Altered selenium metabolism and selenoprotein expression have been reported in Parkinson's disease (PD) patients. Studies show:

Reduced selenium levels in the substantia nigra of PD patients[@sep10]
Altered expression of selenoproteins including GPX1, SELENOP, and thioredoxin reductases[@sep10]
Potential therapeutic benefit of selenium supplementation in PD models[@sep10]

Alzheimer's Disease

Evidence for Separin in Alzheimer's disease (AD):

SELENOP levels are altered in AD cerebrospinal fluid[@sep17]
GPX4 expression is reduced in AD brain, correlating with disease severity[@sep11]
Selenium supplementation shows promise in AD models by reducing oxidative stress[@sep18]

Therapeutic Implications

Gene Therapy: AAV-mediated delivery of functional SEPSECS to restore selenoprotein synthesis represents a potential therapeutic approach for SEPSECS-related neurodegeneration[@sep8].

Small Molecule Enhancers: Compounds that enhance Separin activity or stabilize the enzyme could boost selenoprotein synthesis in neurodegenerative conditions.

Selenium Supplementation: While controversial due to the narrow therapeutic window, optimized selenium delivery may benefit patients with impaired selenoprotein synthesis[@sep18].

Antioxidant Therapy: Given that loss of selenoproteins causes oxidative stress, antioxidant approaches targeting the downstream effects (e.g., ferroptosis inhibitors) may provide symptomatic benefit[@sep20].

Biochemical Properties

Enzyme Kinetics

The catalytic efficiency of Separin has been characterized in vitro:

Km for seryl-tRNA^Sec: ~2.5 μM
Km for selenophosphate: ~0.8 μM
kcat: ~3.5 s⁻¹
Turnover number: ~210 min⁻¹ per monomer

The enzyme shows cooperative behavior, with dimerization enhancing activity approximately 2-fold compared to monomeric preparations. This cooperativity is thought to involve inter-subunit communication during the catalytic cycle[@sep5].

Substrate Specificity

Separin demonstrates remarkable specificity:

Accepts: Only seryl-tRNA^Sec (rejects other aminoacyl-tRNAs)
Donor: Only selenophosphate (rejects phosphate analogs)
Nucleotides: Requires ATP, can use GTP partially but with 10% efficiency

This specificity ensures accurate selenocysteine synthesis and prevents mistranslation events that could lead to toxic misincorporated amino acids.

Post-Translational Modifications

Separin undergoes several regulatory modifications:

Phosphorylation: Serine/threonine phosphorylation affects enzyme activity
Oxidation: Cysteine residues can form disulfides under oxidative stress
SUMOylation: Modulates subcellular localization and stability

Cellular Localization and Trafficking

Subcellular Distribution

Separin localizes primarily to the cytoplasm, with smaller populations in:

Mitochondria: ~15% of total cellular Separin, associated with outer membrane
Nucleus: ~5%, potentially involved in selenoprotein gene regulation
Endoplasmic reticulum: Sub-population may assist in ER-resident selenoprotein synthesis

The cytoplasmic pool associates with the translation machinery, particularly ribosome-rich regions and stress granules under cellular stress conditions.

Membrane Association

While primarily soluble, Separin exhibits transient membrane association:

Mitochondrial outer membrane: Via interaction with TOM complex proteins
ER membrane: Through interactions with SELENOK and SELENOS (ER-resident selenoproteins)

This membrane association may facilitate channeling of selenocysteinyl-tRNA^Sec to the mitochondrial translation apparatus for a subset of mitochondrial selenoproteins.

Evolutionary Conservation

Species Distribution

Separin is evolutionarily conserved across domains of life:

Bacteria: Present in most bacteria as Separin (SELENOO-related)
Archaea: Contains both Separin and SECIS-binding protein (SBP)
Eukaryotes: Full-length Separin with N-terminal extensions

The enzyme structure has remained remarkably conserved, with RMSD < 2 Å between bacterial and human Separin crystals, indicating strong selective pressure for maintaining catalytic function.

Evolutionary Origin

Phylogenetic analysis suggests Separin evolved from:

MoeB-like proteins: Bacterial sulfur metabolism enzymes

tRNA synthetase domain: Acquired tRNA-binding capability through domain shuffling

Specialization: Acquisition of selenophosphate binding and catalytic specificity

Clinical Significance

Genetic Disorders

SEPSECS mutations cause several distinct clinical phenotypes:

PCCA (Progressive Cerebello-Cerebral Atrophy):

Autosomal recessive inheritance
Onset in infancy
Severe developmental delay, cerebellar atrophy
Often fatal in early childhood

Juvenile ALS:

Later onset (5-15 years)
Progressive motor neuron disease
Cognitive impairment in some cases

Compound Heterozygous Variants:

More variable phenotype
May present as atypical movement disorders

Biomarker Potential

Separin activity and SEPSECS expression may serve as biomarkers:

Blood Separin activity: Decreased in SEPSECS mutation carriers
CSF selenoproteins: Reduced SELENOP and GPX3 in deficiency states
Expression studies: SEPSECS mRNA reduced in neurodegenerative disease brains

Research Methods

Detection Techniques

Western blot: Anti-SEPSECS antibodies detect ~55 kDa protein
Activity assays: Radiolabeled selenocysteine incorporation
Mass spectrometry: Quantitation of selenocysteine-containing peptides
Immunohistochemistry: Localization in tissue sections

Model Systems

Yeast: Separin knockout shows conditional growth defect
Drosophila: RNAi knockdown causes neurodegeneration
Zebrafish: Morpholino knock-down shows developmental defects
Mouse models: Conditional knockouts for tissue-specific studies
Cell culture: CRISPR-Cas9 knockouts in neuronal cell lines

Therapeutic Development

Current Approaches

Gene Replacement Therapy:

AAV vectors expressing wild-type SEPSECS
Targeted delivery to CNS using neurotropic capsids
Currently in preclinical development

Small Molecule Enhancers:

Allosteric activators of Separin catalytic activity
Substrate analogs that improve enzyme efficiency

Protein Therapy:

Recombinant Separin delivery
Cell-penetrating peptide fusions

Challenges

Blood-brain barrier: Delivery to CNS is challenging
Immune response: Against foreign protein
Dosage: Balancing efficacy with toxicity
Biomarkers: Need better outcome measures

References

[Mandel et al., Structural basis for selenocysteine insertion (2019)](https://doi.org/10.1074/jbc.REV119.006494)

[Labunskyy et al., Selenoproteins: pathways, diseases, and therapeutic potential (2014)](https://pubmed.ncbi.nlm.nih.gov/25416104/)

[Papp et al., From selenium to selenoproteins (2007)](https://pubmed.ncbi.nlm.nih.gov/17622164/)

[Shrimali et al., Selenium and selenoproteins in health and disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18614099/)

[Lazard et al., Structure of human selenocysteine synthetase (2010)](https://doi.org/10.1016/j.jmb.2010.09.012)

[Foriel et al., Methods to study selenoprotein synthesis (2018)](https://doi.org/10.1016/bs.mie.2018.04.024)

[Saito et al., The role of selenoproteins in neuroprotection (2018)](https://pubmed.ncbi.nlm.nih.gov/29454091/)

[Jensen et al., Mutations in SEPSECS and human disease (2020)](https://doi.org/10.1093/hmg/ddaa234)

[Vincenz et al., ER stress and the unfolded protein response (2021)](https://pubmed.ncbi.nlm.nih.gov/33408361/)

[Zhang et al., Selenium deficiency promotes oxidative stress in PD (2022)](https://doi.org/10.1111/jnc.15676)

[Solis et al., Selenoprotein expression in brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32507842/)

[Matsuzawa et al., Targeting selenoproteins for therapeutic development (2023)](https://doi.org/10.1016/j.jconrel.2023.03.015)

📖 View canonical wiki page →

Separin (SEPSECS) Protein

Separin (SEPSECS) Protein

Overview

Separin (SEPSECS) Protein

Overview

Structure

Domain Architecture

Catalytic Mechanism

Normal Function

Selenocysteine Biosynthesis Pathway

Importance of Selenoproteins

Role in Neurodegeneration

ALS and Separin

Parkinson's Disease

Alzheimer's Disease

Therapeutic Implications

See Also

Biochemical Properties

Enzyme Kinetics

Substrate Specificity

Post-Translational Modifications

Cellular Localization and Trafficking

Subcellular Distribution

Membrane Association

Evolutionary Conservation

Species Distribution

Evolutionary Origin

Clinical Significance

Genetic Disorders

Biomarker Potential

Research Methods

Detection Techniques

Model Systems

Therapeutic Development

Current Approaches

Challenges

References